R&D Trends

BioTime awarded $1.5M grant from the NIH

Monday, September 18, 2017

BioTime, a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases, has been awarded a grant of up to $1.56 million from the Small Business Innovation Research program of the NIH. The grant provides funding to further develop BioTime’s innovative, next generation vision restoration program for more advanced retinal diseases and injuries, which severely impact the quality of life for millions of people with no treatment option. This initiative aims at improving vision in people affected by blindness, whether caused by retinal injuries, age-related macular degeneration, retinitis pigmentosa or other causes.

[Read More]

Survey: Outsourcing R&D services pain points are numerous

Monday, September 18, 2017

More than 100 biotechnology and drug development leaders who responded to surveys conducted during industry conferences earlier this year reported a wide range of barriers to the outsourcing of research and development (R&D) services, including the contracts review process, intellectual property (IP) security concerns and service provider qualification. The surveys were conducted by Science Exchange, a secure platform for outsourced research and development (R&D), during the 2017 Biotechnology Innovation Organization (BIO) International Convention and 2017 Drug Industry Association (DIA) Global Annual Meeting. 

[Read More]

NantHealth, Asia Genomics expand GPS Cancer in Southeast Asia

Tuesday, September 5, 2017

NantHealth, a next-generation, evidence-based, personalized healthcare company, announced that it has entered into an agreement for GPS Cancer, a proteogenomic molecular test that helps guide treatment strategies including choice of standard chemotherapy for oncologists, with Asia Genomics, a provider and distributor of molecular testing services and key player in the field of personalized medicine in Southeast Asia.

[Read More]

Tempus, U of California Davis ink personalized medicine partnership

Tuesday, September 5, 2017

Tempus, a technology company focused on helping doctors personalize cancer care by collecting and analyzing large volumes of molecular and clinical data, and University of California Davis Comprehensive Cancer Center are collaborating on a precision medicine partnership to advance clinical care with Next Generation Sequencing analysis, focused initially on patients diagnosed with hematological malignancies and pancreatic cancer.

[Read More]